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Localization of bradykinin B2 binding sites in the rat kidney following
chronic ACE inhibitor treatment. Bradykinin exerts important influences
on renal hemodynamics and tubular function by acting on renal bradykinin
B2 receptors. However, the precise sites and mechanisms of its actions on
the kidney are not known. To help elucidate the mechanisms of renal
actions of bradykinin in vivo, we have employed high resolution electron
microscopic autoradiography to localize bradykinin B2 binding sites in the
rat kidney following intravenous administration of a radiolabeled ligand,
1251-HPP-Hoel4O (3-4-Hydroxyphenyl-propionyl-DArg°-[Hyp3-Thi5-D-
Tic7-Oic8]-bradykinin), a derivative of the highly selective bradykinin B2
receptor antagonist, Hoel4O. In non-treated rats, bradykinin B2 binding
sites were localized to the cell bodies and the luminal brush border of the
proximal convoluted tubules in the cortex. In the medulla (except for the
Outer stripe of the outer medulla), binding occurred in the distal tubules,
thin limbs of the loop of Henle, collecting ducts, peritubular capillary
endothelium and renomedullary interstitial cells. To exclude the possibil-
ity that the radioligand may bind to angiotensin converting enzyme, rats
were pretreated with the angiotensin converting enzyme inhibitor, penn-
dopril. In these rats, binding to the cell bodies and the luminal brush
border of the proximal convoluted tubules in the cortex was completely
abolished, while binding remained unaltered in the medulla. Further
studies using high performance liquid chromatography revealed that while
the radioligand was degraded following systemic administration in non-
treated rats, the degradation was significantly reduced in the rats pre-
treated chronically with perindopril. These results indicate that binding
detected in the proximal tubules in the normal rats is due primarily to the
tubular uptake of the degraded radioligand, and that bradykinin B2
binding sites occur predominantly in the renal tubules, vascular endothe-
hum, and renomedullary interstitial cells of the renal medulla.
The proposed physiological actions of the renal kallikrein-kinin
system, of which bradykinin (BK) is a member, include regulation
of renal circulation and modulation of tubular electrolyte fluxes
and water transport [1, 2]. In addition, this system interacts with
the renin-angiotensin system and renal prostaglandin systems
[1—31. BK itself can decrease renal vascular resistance, increase
renal blood flow, augment sodium excretion and antagonize
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vasopressin-induced increases in urine osmolarity [2, 4, 5]. BK
could also induce many of these responses indirectly, as it has
been shown to enhance the production of prostaglandins in
cultured renomedullary interstitial cells (RMICs) [6], and in
cultured renal papillary collecting tubule cells [7].
It is now well established that kin ins, including BK, interact with
two types of bradykinin receptor, classified as B and B2 [8]. Most
of the previous interest has focused on the BK B2 receptor, as it
appears to be responsible for the majority of physiological effects
of BK [8]. The BK B2 receptor is a member of the super family of
G-protein coupled receptors characterized by seven transmem-
brane regions [9]. BK acting through BK B2 receptors increases
intracellular calcium concentration, inhibits adenylate cyclase
activity, stimulates the formation of inositol phosphates, and is
dependent on the presence of GTP-binding proteins in neuroblas-
toma cells [10—12]. BK has also been shown to increase phospha-
tidylinositol turnover and stimulate the formation of prostaglan-
dins through activation of phospholipase A2 in Swiss 3T3
fibroblasts [9].
Although BK exerts multiple actions in the kidney, it is unclear
exactly where biologically active BK acts within the kidney.
Previous studies at the light microscopic level have localized BK
binding sites in the kidney [13—15]. Manning and Snyder [14]
reported that in the guinea pig kidney BK binding sites were
found in the inner stripe of the outer medulla, inner medulla, and
the pelvic capsule. However, a precise mapping of the BK B2
subtype binding sites at the electron microscopic level has not
been attempted.
In this study, we have mapped the cellular distribution of the
BK B2 binding sites in the rat kidney at the electron microscopic
level using an in vivo labeling method [16] with the radiolabeled
l'sligand, 1-HPP-Hoe 140. This approach allows high resolution
receptor localization while preserving renal cellular morphology.
The kidney is a very rich source of kinin degrading enzymes [17],
especially kininase TI, otherwise known as angiotensin converting
enzyme (ACE), which is responsible for both conversion of
angiotensin (Ang) I to the vasoconstrictor, Ang II, and the
degradation of bradykinin [18, 19]. Because kininase 11 is present
in great abundance, we assessed the effect of this enzyme on the
cellular localization of renal BK B2 receptors with the radiola-
helcd analogue antagonist, '25l-HPP-Hoel4O, in kidneys of rats
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with or without chronic pretreatment with the ACE inhibitor,
perindopril.
METHODS
Animal pretreatment
Two groups (N = 4) of male Sprague-Dawley rats (200 g body
wt) were used in the present study. One group of rats were treated
with ACE inhibitor, perindopril, for two weeks at 1 mg/kg/day in
their drinking water. Control rats were maintained on normal
drinking water. All animals were fed a normal laboratory rat
chow.
Preparation of radioligand
The antagonist analogue of BK B2 receptors, HPP-Hoe 140 [20],
was iodinated with 125J using the chioramine T method [21]. A
Sep-pak C18 cartridge was used to separate the reaction product
which was eluted with a 40% to 100% gradient of methanol in
0.1% trifluoroacetic acid (TFA), giving an approximate specific
activity of 820 jsCi/g. The radioligand was stored at —20°C and
was stable for at least two months.
In vitro macroscopic autoradiography
Two male Sprague-Dawley rats from each group were killed by
decapitation, the kidneys removed and snap frozen in isopentane
at —40°C. Frozen sections (20 j.tm) were cut in a cryostat and thaw
mounted onto gelatin-chrome alum coated slides, dehydrated at
4°C overnight, and stored at —70°C for up to seven days prior to
use. Slide mounted sections were pre-incubated for 15 minutes at
22°C, in a buffer of 170 mxi Tris-HC1, pH 7.4, containing 0.2%
BSA, to remove endogenous ligand, and then incubated for 24
hours at 4°C in 10 ml of fresh buffer, containing 0.28 jiCi/ml
'251-HPP-Hoel4O. Non-specific binding was determined in paral-
lel incubations in the presence of 1 M unlabeled Hoel4O
(Hoechst AG, Frankfurt, Germany). Sections were rinsed using
ice cold pre-incubation buffer without BSA for 4Xtwo minutes
and exposed for 24 hours against X-ray films (Agfa-Scopic CR3B,
Agfa Gaevert, Belgium). After exposure the autoradiographs
were quantified using a microcomputer imaging device run by an
IBM PC-AT (Imaging Research). The optical density of the
autoradiographs was calibrated in terms of radioactivity density as
disintegrations per minute per square millimeter, with reference
to standards carried through the procedures. A minimum of 20
points from the different regions of each section of kidney were
analyzed. Four sections per animal were included.
In vivo low and high resolution autoradiography
Animals from both treated and non-treated groups were anaes-
thetizcd intraperitoneally with sodium pentobarbitone (Nembu-
tal, Abbott), 60 mg/kg body wt. A catheter was introduced into the
left jugular vein, its tip pointing towards the heart. A second 18 G
hypodermic needle was introduced into the left lower aorta,
towards the heart, its tip remaining below the renal arteries. A
ligature was positioned but not tied around the aorta above the
origin of the right renal artery. Coeliac and superior mesenteric
arteries were tied off in preparation for the perfusion. All
radioactive and other compounds were administered slowly
through the jugular catheter.
In the animals used to ascertain specific binding of the ligand to
BK B2 receptors, 40 tCi of '251-HPP-Hoel4O was infused via the
jugular catheter over a period of two minutes and left to circulate
for 10 minutes. To determine non-specific binding, another rat
was infused with 200 jl of 1 mrvi Hoel4O via the jugular vein
catheter and this was allowed to circulate for 10 minutes, after
which 40 1iCi of radioactive tracer was injected as previously
described.
Following the infusion, the inferior vcna cava was severed and
the ligature tied around the upper aorta and perfusion fixation
began. The kidneys were perfusion fixed at high pressure (200 mm
Hg) with 150 ml of 2.5% glutaraldehyde in phosphate buffer (pH
7.4) over five minutes, After perfusion fixation, the kidneys were
removed. One kidney was snap frozen in liquid nitrogen to be
used for direct dry film macroscopic autoradiography, to deter-
mine the overall distribution of the radioligand. The other kidney
was used for the cellular localization of the '25l-HPP-Hoel4O
binding using light and electron microscopic autoradiography.
In vivo macroscopic autoradiography. For the gross localization
of binding within the kidney, sections (20 Jsm) were cut from the
perfusion fixed kidneys at —20°C, and dried under reduced
pressure in a desiccator at 4°C for at least two hours. The sections
were then exposed to X-ray film as described previously [14] and
quantitation performed as described above.
High resolution light and electron microscopic autoradiography.
For high resolution cellular localization, the fixed kidneys were
sliced into blocks 1 mm X 1 mm from the cortex, the outer stripe
of the outer medulla, the inner stripe of the outer medulla and the
inner medulla. The blocks were further fixed in 2.5% glutaralde-
hyde in 0.1 M phosphate buffer containing 5% sucrose overnight,
then post-fixed in 2.5% aqueous osmium tetroxide, dehydrated in
graded acetone and embedded in araldite (Ciba-Geigy, Basel,
Switzerland).
To permit high resolution localization of '251-HPP-Hoel4O
binding at the light microscopic level, tissue blocks were sectioned
(1 jim) and positioned on chrome alum coated glass slides, then
dipped in Ilford KS emulsion (Ilford, Mobberly Cheshire, UK)
and exposed at 4°C for 10 weeks. After exposure, the slides were
developed in Kodak D19, and lightly counter stained with 1%
methylene blue for light microscopic examination.
For electron microscopic autoradiography, thinner sections (60
to 90 nm) were cut on a diamond knife and positioned on celloidin
coated glass slides. The slides were then coated with Ilford KS
emulsion and exposed at 4°C for up to 80 days. Following
exposure, slides were developed in Kodak D19, stained with
uranyl acetate and lead citrate, and examined in a Philips CM12
electron microscope.
Determination of '251-HPP-Hoel4O degradation
To determine whether the radioligand was significantly de-
graded following in vivo administration, animals from both treated
(N = 2) and non-treated groups (N = 2) were anesthetized
intraperitoneally with sodium pentobarbitone (Nembutal, Ab-
bott), 60 mg/kg body wt. A catheter was introduced into the left
jugular vein, its tip pointing towards the heart. Forty microCuries
of 1251-HPP-Hoel4O was infused via the jugular catheter over a
period of two minutes and left to circulate for 10 minutes. An
aliquot of non-infused 1251-HPP-Hoel4O was kept as a control.
Following infusion, the kidneys from both chronic ACE inhibitor
treated rats and non-treated rats were removed, finely diced (1
mm3) and suspended in a 170 mivi Tris-HC1 buffer (pH 7.4)
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Fig. 1. Autoradiographs showing gross anatomic distribution of '251-HPP-Hoe!40 binding in the rat kidney following in vitro incubation or
intravenous administration of the ligand. (a) In vitro incubation with '251-HPP-Hoe140, (b) non-specific binding in the presence of 1 rM unlabeled
Hoel4O, (c) in vivo or intravenous administration of '251-HPP-Hoel4O, and (d) non-specific binding after the in vivo administration of an excess of
Hoel4O. Abbreviations are: C, cortex; IS, inner stripe of the outer medulla; TM, inner medulla.
containing 0.1% TFA. Each suspension was homogenized (Ultra-
turrax T-25, Jankie and Kunkel, Staufen, Germany) and centri-
fuged at 1000 Xg for five minutes at 4°C (Beckman GPR
Centrifuge; Beckman Instruments, Fullerton, CA, USA). The
supernatants were collected and centrifuged for 30 minutes at
50,000 Xg at 4°C (Beckman XL-90, Ultracentrifuge, SW41Ti
rotor). The supernatants resulting from ultraspeed centrifugation
were then injected into a Sep-pak C18 column and eluted with
80% MeOH in 0.1% TFA. The elutants were concentrated under
a stream of cold air and stored at —20°C until the high pre-
formance liquid chromatography (HPLC) separation. Sample
degradation was determined using a Waters HPLC system com-
prising of an automated gradient controller, two pumps (Model
510), an autosampler (Model 712, WISP) and a detector (Model
441). Briefly, two samples from each animal were separated on a
Novapak C18 column (Waters Associates) contained within a
radial compression unit by elution with a 2.1% acetonitrile in
0.08% TFA to 70% acetonitrile in 0.08% TFA linear gradient at
a rate of I mi/mm. The degradation of '25T-HPP-Hoel4O was
monitored by the radioactivity present in the I ml fractions
collected during the course of the HPLC separation and com-
pared to the trace given by radioligand that had not been infused
into the rat.
RESULTS
In vitro autoradiographic localization of '251-HPP-Hoel4O
binding
The gross anatomical distribution of BK B2 binding sites is
shown in Figure Ia. '25T-HPP-Hoel4O binding occurred in well-
defined stripes throughout the medulla with the highest density
seen in longitudinal bands traversing the inner stripe of the outer
medulla. Binding was very low to undetectable in the outer stripe
of the outer medulla. Little binding was observed in the entire
cortex. All binding in the medulla was specific, since binding was
completely abolished by 1 M unlabeled Hoel4O (Fig. Ib).
Quantitative data are given in Table I.
Localization of BK B2 binding sites following intravenously
administered '251-HPP-Hoel4O
Low resolution localization. As shown in Figure ic, the gross
patterns of anatomical distribution of '251-HPP-Hoel4O binding
in the kidney, following intravenously administered '251-HPP-
Hoei4O in vivo, are essentially the same as that revealed by in vitro
labeling (Fig. 1 a). Quantitative data are given in Table 1. Animals
cironically treated with an ACE inhibitor also showed very similar
patterns of 251-HPP-Hoel4O binding compared to non-treated
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Table 1. Densities of 251-HPP-Hoel4O binding in different anatomic
sites of rat kidney as determined by quantitative in vivo and in vitro
autoradiography
In vitro In vivo
TB NSBTB NSB
TM 417 15 ND 211 10 30 10
ISOM 583 24 ND 318 11 44 2
Cortex 11 6 ND 109 9 78 9
Data are means SD in disintegrations min' mm2 and were derived
from at least 20 samples from each site in at least 4 sections of rat kidney.
Abbreviations are: TM, inner medulla; ISOM, inner stripe of the outer
medulla; ND, not detectable; TB, total binding; NSB, non-specific binding.
animals (not shown). In all cases intense labeling occurred in the
inner medulla, and also in longitudinal bands that traverse the
inner stripe of the outer medulla. In the medulla, labeling was
almost completely abolished by an excess of unlabeled Hoel4O
administered intravenously 10 minutes before giving 1251-HPP-
Hoel4O. However, a low level of labeling persisted in the cortex
(Fig. id).
High resolution light microscopic autoradiographic localization.
In the cortex of non-treated animals a high level of labeling was
detected overlying the tubular components (Fig. 2a); however,
this was absent in animals that had been on perindopril treatment
(Fig. 3 a, b). No specific silver grains were detected overlying
glomeruli of the renal cortex in either the treated or non-treated
animals.
No specific silver grains were detected in any structures of the
outer stripe of the outer medulla in the treated or non-treated
animals (not shown). In the inner stripe of the outer medulla, of
both treated (Fig. 3 c, d) and non-treated (not shown) animals,
specific silver grains were detected overlying the components of
the vasa recta bundles and interstitium. The areas between the
vasa recta bundles of both groups showed silver grains overlying
tubular structures.
The inner medulla of both treated (Fig. 3 e, f) and non-treated
(not shown) groups showed silver grains overlying tubular struc-
tures and interstitium. No specific silver grains were observed in
kidneys from rats receiving unlabeled Hoel4O prior to the 1251
HPP-Hoel4O (Fig. 3 g, h).
Electron microscopic autoradiographic localization. In perindo-
pril treated animals, no specific silver grains were detected in the
structures of the cortex; however, silver grains were detected
overlying the brush borders and cell bodies of the proximal
convoluted tubules in non-treated animals (Fig. 2b).
In the outer stripe of the outer medulla, no specific grain
development was detected in the treated animals. However, silver
grains were detected overlying the proximal tubule cells in the
non-treated animals. In the inner stripe of the outer medulla,
silver grains were specifically localized to the components of the
Fig. 2. Light (a) and electron (b) micrographs of emulsion autoradio.
graphs, from non-treated rats, following intravenous administration of
'251-HPP-Hoel4O. Abbreviations are: G, glomerulus; P, proximal convo-
luted tubule and B, brush border membrane of proximal convoluted
tubule. Stains; methylene blue (a) and uranyl acetate and lead citrate (b).
Magnifications; (a) X530 and (b) x6000. Micrographs (a) and (b) show
silver grains overlying the proximal convoluted tubule cell body and brush
border.
vasa recta bundles, such as the thin limbs, peritubular capillary
endothelium, and renomedullary interstitial cells (RMICs; Fig. 4
d, e, f). Silver grains were also detected overlying the cells of the
distal tubules and collecting ducts (Fig. 4 a, b, c). The distribution
of 1251-HPP-Hoel4O binding was similar for both treated and
non-treated animals. In the inner medulla of both treated and
non-treated animals, silver grains were localized to the thin limbs
(Fig. 5c), collecting ducts (Fig. 5 a, b) and RMICs (Fig. 5 b, d).
At the electron microscopic level, no silver grains were detect-
able in the rats given unlabeled Hoel4O before injection of the
radioligand (not shown).
Fig. 3. Light and dark field micrographs of emulsion autoradiographs of thick plastic sections from Perindopril pretreated animals; (a and b) renal
cortex, (c, d, g and h) inner stripe of the outer medulla and (e and J) inner medulla from a rat kidney following intravenous administration of
'251-HPP-Hoel4O, total binding (a-f) or in the presence of an excess (1 M) of unlabeled Hoel4O for non-specific binding (g and h). Methylene blue
Stain. Magnification of all micrographs is X530. Arrows indicate silver grains overlying the interstitium. Abbreviations are: G, glomerulus; CD, collecting
duct; P, proximal tubule; VRB, vasa recta bundle. (a and b) No specific binding is detectable overlying the structures of the renal cortex. (c and d)
Specific binding of 1251-HPP-Hoel4O, indicated by silver grains, is detected overlying the vasa recta bundles and tubular components of the inner stripe
of the outer medulla. (e and f) In the inner medulla silver grains overly tubular and vascular structures as well as the interstitium. (g and h) Non-specific
binding in the inner stripe of the outer medulla is undetectable.
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Fig. 4. Electron micrographs of emulsion autoradiographs of thin plastic sections of the inner stripe of the outer medulla from rats pretreated with
perindopril, following intravenous administration of 1251-HPP-Hoel4O. Abbreviations are: D, distal tubule; CD, collecting duct; IC, interstitial cell; Th,
thin limb of loop of Henle; EC, endothelial cell. Uranyl acetate and lead citrate stain. Magnifications are: (a) ><6000, (b) ><7600, (c) >(6000, (d)
X12600, (e) X7600 and (f) x7600. Specific silver grains overlying distal tubules (a and c), collecting duct (b), thin limb of the loop of Henle (d and
e), interstitial cells (d and f) and endothelial cells (e and f) of the inner stripe of the outer medulla.
1251-HPP-Hoel4O degradation
The HPLC purification profiles are shown in Figure 6. The
curves shown are representative of those obtained in the duplicate
samples from both animals. The non-infused (control) tracer
produced a single peak when separated on the Novapak C18
column by HPLC suggesting that it is intact. In contrast, the
radioligand infused into the non-treated rats was degraded as
shown by the appearance of major peaks at fractions 19, 20 and
21. On the other hand, the radioligand infused into the ACE
inhibitor (ACE1) treated rats was only minimally degraded. This
difference of HPLC profiles suggests that the ACEI largely
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Fig. 5. Electron micrographs of emulsion autoradiographs of thin plastic sections of the inner medulla from rats pretreated with perindopril, following
intravenous administration of '251-HPP-Hoel4O. Abbreviations are: CD, collecting duct; EC, endothelial cell; IC, interstitial cell; ICP, interstitial cell
processes; Th, thin limb of the loop of Henle. Uranyl acetate and lead citrate stain. Magnifications are: (a) x6000, (b) x12600, (c) x7600 and (d)
xl0000. Specific silver grains overlying a collecting duct (a and b), endothelial cells (a and d), interstitial cells (b and c), and thin limb of the loop of
Henle (c).
prevented the degradation of the radioligand '251-HPP-Hoe140.
The HPLC profiles shown were consistant within animal groups.
DISCUSSION
In this study renal BK B2 receptors have been mapped by
utilizing the radiolabeled analogue (1251-HPP-Hoe 140) of the BK
B2 receptor antagonist Hoel4O, a pharmacologically potent BK
B2 receptor antagonist [20]. Its parent compound, Hoel4O, has a
long duration of action and is devoid of a BK-like agonistic effect
[22, 23]. The results of the present study show that BK B2 binding
sites occur widely in the components of the vasa recta bundles,
capillary endothelial cells, epithelial cells of the thin limbs, distal
tubule, collecting duct and the RMICs in the inner stripe of the
outer medulla. In the inner medulla, BK B2 binding sites are
localized to the RMICs, the loops of Henle, capillary endothelium
and the collecting duct epithelial cells. In the cortex, however, low
levels of binding were detected in the epithelial cells of proximal
tubules only in rats without ACE inhibitor pretreatment. These
findings confirm and extend previous studies using low resolution
localization [24].
In the non-treated rats, binding occurred over the brush border
membranes and cell bodies of the proximal convoluted tubules.
One of the main in vivo functions of the proximal tubules is to
breakdown and reabsorb, via endocytosis, any macromolecules
that have managed to pass through the glomerular filtration
barrier; these macromolecules are then degraded in lysosomes. As
this binding is not abolished by an excess of unlabeled Hoel4O, it
is most likely non-specific. As high levels of ACE or kininase II
are located within the proximal tubule brush border [17—19],
the ligand may be processed and endocytosed by the tubules.
To test this hypothesis we chronically treated rats with the ACE
inhibitor, perindopril. Following perindopril treatment, label-
ing in the proximal tubules was dramatically reduced. Thus, we
believe that the labeling may be due to the uptake of the
fragments of the degraded radioligand, by the scavenger pro-
cesses of the proximal tubules, therefore not representing
specific BK B2 binding sites.
This phenomenon would only be seen in animals where the
1251-HPP-Hoel4O is administered via the circulation (in vivo). In
previous BK B2 binding site localization studies using frozen or
fixed tissues, active breakdown of the ligand would not occur. This
explains why no cortical labeling is detected in macroscopic
sections incubated in the presence of the 1251-HPP-Hoel4O. It is
also likely that other enzymes are partly involved in ligand
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Fig. 6. HPLC analysis of radioligand bound to kidney tissue. The
authentic radioligand shows a major peak at fraction 24. The tracer,
extracted from kidneys of animals given an ACE inhibitor, also chronically
produced a peak at fraction 24. However, the tracer extracted from the
kidneys of non-treated rats was eluted at fraction 20. This shows that there
is a different molecule than the original HPP-Hoe140 attached to the 251
in rats not given ACEi treatment. The ACEi appears to stop, to some
extent, degradation of the 251-HPP-Hoe140 in the rat in viva. Symbols
are: (•) tracer alone; (•) chronic ACEi treatment; (A) no treatment.
breakdown as some smaller peaks present on the HPLC profile
are present in both treated and non-treated animals, but are not
seen with tracer alone. This indicates that ACEi did not com-
pletely stop degradation. Therefore, ACEi prevented, at least to
some extent, the degradation of the radioligand, though the
precise enzyme and mechanisms involved in Hoel4O degradation
remain unknown at the present time.
Although considerable interest has been focused on the kal-
likrein-kinin system in the kidney, no clear physiological role has
yet been determined. Defining the exact cellular localization of
the BK B2 binding sites may help to explain some of the known
actions of BK in the kidney. The presence of the components of
the kallikrein-kinin system in the distal nephron has been well
documented. Kininogen [25], kallikreins [26], kininases [17—191,
and kinins have all been found there [27], showing that the distal
portion of the nephron has the substrate and enzyme to generate
kinins locally within the kidney. Our studies demonstrate that
these distal tubule cells and also epithelial cells in further portions
of the nephron have BK B2 binding sites. It is reasonable to
assume that the distal nephron is not only the major site of kinin
formation, but that it is also a major site of kinin action.
Significant diuresis and natriuresis have been observed after
intrarenal BK infusion [281 with no change in glomerular filtration
rate, implying the maintenance of filtration autoregulatory mech-
anisms. This response may be explained by a direct tubular action
of BK, rather than effect of a change in the filtration processes of
the glomerulus.
One of the most important features of the medulla is the
presence of vasa recta bundles forming part of the countercurrent
concentrating mechanism. Interstitial hypertonicity is a key fea-
ture in the efficiency of this mechanism and medullary blood flow
regulates interstitial hypertonicity. Therefore, to achieve a con-
stant and effective mechanism, blood flow must be tightly regu-
lated. The lower the blood flow in the medulla, the more
hypertonic is the interstitium, and the more concentrated the
urine. The major components of the vasa recta bundles are the
loops of Henle, vasa recta and RMICs, which are all possibly
involved in the regulation of blood flow.
Administration of BK can induce both a natriuresis and diuresis
[28, 291. The contribution of altered renal plasma flow to this
response cannot totally be eliminated; however, the fact that
glomerular filtration rate is usually unaffected suggests that BK
directly influences renal tubular transport. Micropuncture studies
indicate that even though BK causes a rise in proximal tubule
cAMP [30, 31] it does not affect solute reabsorption [32]. This is
supported by the absence of binding sites on the glomeruli and
proximal tubules. However, the loop of Henle, which the current
study is demonstrated to have BK B2 binding sites, plays a critical
role in the regulation of salt and water excretion and is a possible
site of BK action in the rat. BK has also been shown to
significantly inhibit Cl — transport in the in vitro microperfused
medullary thick ascending limb [331
The vasa recta may play an important role in the regulation of
medullary blood flow via interactions between BK and prostaglan-
dins [31. Several of the physiological effects of BK may be related
to an increase in intrarenal prostaglandin levels. Blockade of
prostaglandin synthesis by indomethacin partly prevents the va-
sodilatory actions of kinins in isolated blood vessels [351. It has
been hypothesized that the renal kallikrein-kinin system is acti-
vated by the renin-angiotensin system to protect the renal vessels
against constriction under the influence of endogenous Ang II
[361. This suggests important interactions between Ang II and BK
in the control of medullary circulation. Physiological studies have
provided evidence that All decreases outer medullary and papil-
lary blood flow, a mechanism that may be secondary to kinin
release [37]. This action of BK would cause some wash-out of the
medullary gradient, therefore decreasing the amount of sodium
and water reabsorbed.
RMICs are also a component of the vasa recta bundles.
Frederick et al [38] were the first to demonstrate the presence of
BK B2 receptor-like binding activity in the cultured RMIC [38],
the results of which are supported by the current study. The type
I interstitial cell, with its dense cytoplasmic lipid droplets, is very
abundant in the medulla [391, and appears to be one of the main
target cells of the BK peptide. RMICs lie traversely between the
tubules and the blood vessels, in close apposition to the collecting
duct cells. It has been proposed that RMICs are capable of
adjusting the distance between the tubules and vessels [39]. BK
has been shown to act on these cells to produce prostaglandins [6],
which in turn can have widespread influences on medullaty
structures. Prostaglandins can antagonize the effects of vasopres-
sin on collecting ducts, which may explain the diuretic actions of
BK. Prostaglandins also inhibit sodium reabsorption in collecting
tubule cells causing natriuresis and diuresis [40].
The collecting tubules, which have been shown to possess BK
B2 binding sites, can actively synthesize prostaglandins [7] and it is
well known that kinins are potent stimulators of renal prostaglan-
din synthesis [6, I. The collecting duct, a site of fluid reabsorp-
tion, is therefore a possible site of BK action. It is generally
assumed that kinins influence the reabsorption of sodium and
water in the collecting duct [29, 41], based on findings that
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infusion of BK into the renal artery of dogs increased sodium
excretion without altering proximal tubule reabsorption [42]. This
proposed action of BK on the collecting duct is supported by our
observation of BK B2 binding sites on collecting duct epithelial
cells.
Previous studies have demonstrated the presence of BK binding
sites on cultured glomerular mesangial cells, detailing the second
messenger systems and contractile actions associated with these
binding sites [43]. The present study, however, did not detect the
presence of these BK binding sites under in vivo conditions,
suggesting that the cultured mesangial cells may acquire the BK
binding sites in vitro. BK binding sites on mesangial cells are
thought to play a role in the renal hemodynamic effect of BK.
Conversely, we suggest that the endothelial BK binding sites
within the medullary portion of the kidney are more likely to be
involved in BK's effect on renal hemodynamics. The failure of
Hoel4O, the specific BK B2 antagonist, to affect renal blood flow
in normotensive rats does not support a major role of kinins in the
regulation of overall renal hemodynamics [231, even though
intrarenal kinins may have an important influence on the regula-
tion of papillary blood flow [44].
In summary, BK B2 binding sites were localized to the compo-
nents of the vasa recta bundles, including capillary endothelial
cells, epithelial cells of the thin limbs and RMICs, as well as distal
tubule and collecting duct epithelial cells of the inner stripe of the
outer medulla. In the inner medulla BK B2 binding sites were
localized to the loops of Henle, collecting ducts, RMICs and
capillary endothelium. As BK induces vasodilator and natriuretic
effects and because multiple localizations of BK binding sites have
been reported along the nephron, both in the current study and
previously [13, 15, 38], it appears possible that these binding sites
transduce in different ways the renal responses to BK.
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APPENDIX
Abbreviations used in this study are: BK, bradykinin; RMIC, renomed-
ullary interstitial cells; ACE, angiotensin inhibitor enzyme; ACEi, ACE
inhibitor; HPLC, high preformance liquid chromatography; Ang, angio-
tensin; TFA, trifluoroacetic acid.
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